Special Issue

Resistance to Cancer Immunotherapy

Guest Editors:

Prof. Gerhard Hamilton,
Head of the Surgical Research Lab at the Department of Surgery, Medical University of Vienna; Leading member of the Ludwig Boltzmann Cluster of Translational Oncology.

Department of Surgery, Medical University of Vienna, Vienna, Austria.
Email: Gerhard.Hamilton@toc.tbg.ac.at

Submission Deadline: 31 Jan 2020

Special Issue Introduction

Cancer immunotherapy, especially in form of the inhibition of checkpoint molecules, has significantly improved the outlook of melanoma, lung cancer and other patients. However, of the approximately 45% of cancer patients eligible for immunotherapy only about 13% of cases are responders leaving the remaining population exposed to a therapy which has less side effects than chemotherapy but is not free of a range of adverse events. Assessment of PD-L1 expression and tumor mutational burden (TMB) enrich suitable patients but cannot actually predict responses. Furthermore, tumors may become resistant to immunotherapy either by changing their own characteristics or by generating an immunosuppressive microenvironment. For this issue, work on all aspects of mechanisms that renders immunotherapy ineffective is invited. This comprises the range of different immune checkpoint molecules and the modulation of their expression, tumor infiltration, immunosuppressive leukocyte populations as well as the effects of chemotherapy in combination trials and more. In particular, the ongoing study of drugs that can convert a cold tumor to a hot one or provide accessory stimulation of the immune system is of special interest to overcome resistance. Another current focus is the selection of markers to rapidly evaluate the success of an ongoing immunotherapy, including the detection of resistance. Future directions for the improvement of immunotherapy may involve combination therapy with other immune modulators, oncolytic viruses, vaccines, radiation treatment, chemotherapy, targeted therapy, or antiangiogenic therapy to achieve its full potential and to overcome resistance. In summary, the objective of this series is to explore the current successes and failures, and discuss the future directions of immunotherapy as a means of treating cancer.

Benefits

Rigorous mechanism in peer review: one manuscript must be reviewed by at least two relevant experts. We will endeavour to ensure high standards for the review process and subsequent publication by a team of efficient and professional reviewers and scientific editors.

No publication fee: there would be absolutely no charge for publication.

Rapid publication: we will ensure that accepted papers will be published in a short processing time (the average processing time: 50.7 days) with a high quality.

Open Access: As an author you will retain the copyright to your work. By licensing your work under the Creative Commons Attribution License, articles can be re-used and re-distributed without restriction, as long as the original work is correctly cited.

Wide promotions: Published articles will be promoted at academic conferences, through social networks for scientists and relevant indexing services.